Japan records surprise trade deficit in July as exports weaken further
Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals PLC (NASDAQ:CNTA), sold 6,000 ordinary shares of the company on August 15, 2025, for $17.23, totaling $103,380. The sale comes as Centessa’s stock trades near its 52-week high of $19.09, with the company’s market capitalization reaching $2.37 billion.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed. Hussain also exercised options to acquire 6,000 ordinary shares at a price of $5.84, for a total value of $35,040. InvestingPro data shows the stock has delivered a strong 37.9% return over the past year, though technical indicators suggest the stock is currently in overbought territory.
Following the sale, Hussain directly owns 105,386 ordinary shares of Centessa Pharmaceuticals. The sale was executed under a Rule 10b5-1 trading plan adopted on September 14, 2024. For more detailed insights and 11 additional exclusive tips about Centessa, visit InvestingPro.
In other recent news, Centessa Pharmaceuticals has caught the attention of analysts and investors with several key developments. Truist Securities initiated coverage on Centessa Pharmaceuticals with a Buy rating, setting a $30.00 price target. The firm highlighted the potential of Centessa’s Orexin-2 receptor agonist, ORX750, which is designed to treat narcolepsy and idiopathic hypersomnia. Additionally, Piper Sandler maintained its Overweight rating on the company, with a price target of $38.00, following discussions with a sleep medicine specialist about the prospects of ORX750.
In corporate news, Centessa Pharmaceuticals announced the appointment of Raphael Deferiere as the new Chief Accounting Officer, effective May 27, 2025. Deferiere, who has a background as an Assurance Partner at Ernst & Young, brings substantial experience to his new role. These recent developments underscore the ongoing interest in Centessa’s efforts to address sleep disorders through innovative treatments. Investors are keeping an eye on upcoming data readouts from the Phase 2 CRYSTAL-1 study, expected in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.